Incyte Corp.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Incyte Corp.
Former names: Incyte Genomics Inc Incyte Pharmaceuticals Inc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 8731 — Services-Commercial Physical & Biological Research
Jurisdiction of incorporation: Delaware
Headquarters city: Wilmington
Headquarters state / province: Delaware
Headquarters country: United States
Fiscal year end: December
Ticker symbol: INCY
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000879169
EIN: 94-3136539
Wikidata ID: Q6015591

Board of directors

Follow this board

Edmund Harrigan · Director
Since 2023
Felix Baker · Director Overboarded
Since 2023
Herve Hoppenot · Director · Special Advisor to the CEO
Since 2023
Jacqualyn A. Fouse · Director
Since 2023
Jean Jacques Bienaime · Director Overboarded
Since 2023
Julian Baker · Director Overboarded
Since 2023
Katherine A. High · Director
Since 2023
Otis W. Brawley · Director
Since 2023
Paul J. Clancy · Director
Since 2023
Susanne Schaffert · Director
Since 2023
William Meury · Director · Chief Executive Officer
Since 2025

Chief executives

William Meury · Chief Executive Officer

Since June 2025

100 CEO score

Outstanding · grade A+

Out of 100, from shareholder return, dividends, growth and acquisitions.

Partial: only 35% of the scoring weight is on file.

Revenue growth 20%: 100
Earnings growth 15%: 100

35% of the scoring weight is on file. Figures cover December 2024 – December 2025.

Herve Hoppenot · Chairman / CEO

Until June 2025 · Former

Director election results

Annual meeting of June 10, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

11 of this board's directors also sit on 29 other boards. 28 are in the same sector.

Shared director Other board Same sector +13 more in the list below

ACADIA Pharmaceuticals Inc. Same sector
via Edmund Harrigan, Felix Baker and Julian Baker
Bicycle Therapeutics plc Same sector
via Felix Baker, Herve Hoppenot and Julian Baker
Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker, Jacqualyn A. Fouse and Julian Baker
BeOne Medicines Ltd. Same sector
via Felix Baker and Julian Baker
DBV Technologies S.A. Same sector
via Felix Baker and Julian Baker
Denali Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Kymera Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated Same sector
via Felix Baker and Julian Baker
Replimune Group Inc. Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
vTv Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Agilent Technologies Inc.
via Otis W. Brawley
Agios Pharmaceuticals Inc. Same sector
via Jacqualyn A. Fouse
Ascendis Pharma A/S Same sector
via Jean Jacques Bienaime
BioMarin Pharmaceutical Inc. Same sector
via Jean Jacques Bienaime
BioNTech SE American Depositary Share Same sector
via Susanne Schaffert
CRISPR Therapeutics AG Same sector
via Katherine A. High
Immunome Inc. Same sector
via Jean Jacques Bienaime
Keros Therapeutics Inc. Same sector
via Jean Jacques Bienaime
Lyell Immunopharma Inc. Same sector
via Otis W. Brawley
Maze Therapeutics Inc. Same sector
via Herve Hoppenot
PDS Biotechnology Corporation Same sector
via Otis W. Brawley
Sionna Therapeutics Inc. Same sector
via Paul J. Clancy
Syndax Pharmaceuticals Inc. Same sector
via William Meury
Xilio Therapeutics Inc. Same sector
via Paul J. Clancy

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $66,109,866; 49 sales by 8 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+8,539	$68.62	$585,946
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+12,335	$72.27	$891,450
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+16,428	$80.50	$1,322,454
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+15,054	$74.78	$1,125,738
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+23,526	$77.67	$1,827,264
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+18,331	$61.76	$1,132,123
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+19,749	$61.18	$1,208,244
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+12,305	$64.25	$790,596
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+6,907	$68.25	$471,403
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+16,428	$85.01	$1,396,544
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+12,743	$90.56	$1,154,006
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+15,054	$83.58	$1,258,213
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+24,838	$83.20	$2,066,522
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+879	$113.64	$99,890
Nov 6, 2026	Stein Steven H Officer (CMO & Head of Late-Stage Dev.)	Option exercise	+17,986	$113.64	$2,043,929

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Incyte Corp.

Who is the CEO of Incyte Corp.?

William Meury has been Incyte Corp.'s Chief Executive Officer since June 2025.

How many directors are on Incyte Corp.'s board?

Incyte Corp.'s board has 11 directors: Edmund Harrigan, Felix Baker, Herve Hoppenot, Jacqualyn A. Fouse, Jean Jacques Bienaime, Julian Baker, Katherine A. High, Otis W. Brawley, Paul J. Clancy, Susanne Schaffert and 1 other.

Are Incyte Corp. insiders buying or selling shares?

Over the last 12 months, Incyte Corp. insiders made no open-market purchases and sold $66.1 million of shares in 49 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Incyte Corp. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="incyte-corp"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.